Reply
Tue 11 Oct, 2011 09:06 am
Context:
No matter how vigorous and successful the efforts to combat antibiotic resistance might be, new antibiotics will still be urgently needed. 17,20,23 Since the net present value of antibiotics is low, the development of new antibiotics is not a high priority for pharmaceutical companies. New approaches to overcoming the barrier to drug development have been proposed, including orphan drug benefits, government support for antibiotic development, prolonged patents, expedited approval, and other strategies. 17 Again, talk will not be enough, and efforts to stimulate new antibiotic development must be paired with even more aggressive programmes and policies to limit inappropriate use in human beings, animal husbandry, and aquaculture.
@oristarA,
An "orphan drug" is a medicinal agent specifically developed to treat or cure a rare disease. Since the market for these drugs might be very limited, pharmaceutical companies might be reluctant to invest in their development unless they are given a financial incentive to do so.
"orphan drug benefits" refers to the financial, or other, incentive provided to pharmaceutical companies to encourage the development of drugs designed to target specific rare diseases.
Selected Answer
Stumble It!
Tweet This
Bookmark on Delicious
Share on Facebook
Share on MySpace